Bausch + Lomb expands OTC product line with $106.5M acquisition of Blink eye drops from J&J

Bausch + Lomb Corp. of Bridgewater recently said it purchased the Blink product line of eye and contact lens drops from Johnson & Johnson Vision for $106.5 million.

The acquisition is the latest example of the company’s commitment to increasing over-the-counter consumer convenience in eye care.

“There’s a growing need for relieving the symptoms of dry eyes and dry contact lenses, and OTC products are often the first option consumers choose,” John Ferris, executive vice president, consumer, Bausch + Lomb, said. “The addition of Blink expands our robust portfolio of OTC eye care brands, enabling us to provide more choices for consumers and eye care professionals.”

The company pointed to a 2022 survey that showed more than half (57%) of American adults suffer from dry eyes, and nearly half (48%) use OTC remedies.